Keyphrases
Novel Hybrids
100%
Exendin-4 (Ex-4)
100%
Antidiabetic
100%
Gastrin
100%
Xenin-25
100%
Glucose-dependent Insulinotropic Polypeptide
72%
Glucagon-like
27%
Diabetes
18%
High-fat Diet
18%
Metabolic Effects
18%
Insulinotropic Effects
18%
Biological Activity
9%
Twice Daily
9%
Food Intake
9%
Glucagon
9%
Insulin Secretion
9%
Novel Treatment
9%
Plasma Insulin
9%
Insulin Sensitivity
9%
B Cells
9%
Energy Consumption
9%
Cell Area
9%
Locomotor Activity
9%
Unimolecular
9%
Biological Action
9%
High-fat Diet Mice
9%
Glucose-lowering Drugs
9%
Pancreatic β-cells
9%
Glucose-insulin System
9%
A1 Receptor
9%
Glucose Tolerance
9%
Acute Administration
9%
Fat Mass
9%
Enteroendocrine
9%
Amylase Activity
9%
Pancreatic Cells
9%
Therapeutic Utility
9%
Metabolic Response
9%
LDL Cholesterol
9%
Agonist Peptide
9%
Biological Therapeutics
9%
Peptide Hormone
9%
Pharmacology, Toxicology and Pharmaceutical Science
Peptide
100%
Antidiabetic Agent
100%
Exendin 4
100%
Gastrin
100%
Gastric Inhibitory Polypeptide
72%
Mouse
36%
Insulin
36%
Fat
36%
Glucose
27%
Diabetes Mellitus
18%
Glucagon-Like Peptide-1
18%
Biological Activity
9%
Hormone
9%
Glucagon
9%
Low Density Lipoprotein Cholesterol
9%
Glucagon-Like Peptide 1 Receptor
9%
Peptide Hormone
9%
Amylase
9%
Neurotensin Receptor
9%
Biochemistry, Genetics and Molecular Biology
Hybrid
100%
Peptide
100%
Glucose
100%
Gastrin
100%
Mouse
36%
Fat
27%
Glucagon-Like Peptide-1
18%
Reduction (Chemistry)
9%
Glucagon
9%
Insulin Release
9%
Body Weight
9%
Metabolic Pathway
9%
Insulin
9%
Insulin Sensitivity
9%
Energy Expenditure
9%
Biological Activity
9%
Insulin Blood Level
9%
Glucagon-Like Peptide 1 Receptor
9%
Fat Mass
9%
Modulation
9%
Agonist
9%
Body Fat
9%
Peptide Hormone
9%
Cholesterol
9%
Locomotion
9%
Insulin Like Activity
9%
Amylase
9%
Neurotensin Receptor
9%
Chemistry
Gastrin
100%
Neurotensin
9%
Peptide Hormone
9%